Nivolumab vs Warfarin
Nivolumab vs Warfarin: Overview
This comparison examines the pharmacological differences between Nivolumab and Warfarin.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Warfarin: Inhibits vitamin K epoxide reductase complex.
Pharmacokinetics
Half-life: Nivolumab β 27 days; Warfarin β 20-60 hours.
Chemical Properties
Molecular Formula: Warfarin β C19H16O4.
Molecular Weight: Warfarin β 308.3280 g/mol.
Type: Nivolumab β Antibody; Warfarin β Small molecule.